阿塔鲁伦通过恢复核糖体生物合成和降低p53水平改善Shwachman-Diamond综合征细胞的髓系生成和中性粒细胞趋化
Shwachman-Diamond综合征(SDS)以中性粒细胞减少、外分泌胰腺功能不全和骨骼异常为特征,骨髓造血祖细胞凋亡增加且粒细胞分化受损。本研究在体外和离体评估阿塔鲁伦对SDS来源细胞的功能恢复作用,发现其改善80S核糖体组装和总蛋白合成、恢复髓系祖细胞髓系生成、改善中性粒细胞趋化并减少中性粒细胞发育异常标志,且在原代成骨细胞中恢复全长SBDS合成。
要点
- 阿塔鲁伦改善SDS来源细胞的80S核糖体组装和总蛋白合成。
- 阿塔鲁伦恢复SDS髓系祖细胞的髓系生成并改善中性粒细胞趋化。
- 阿塔鲁伦在原代成骨细胞中恢复全长SBDS合成,作用可能超出髓系。
核心结论
- 结果强化了在携带无义突变的SDS患者中进行阿塔鲁伦I/II期临床试验的依据。
研究设计与样本
- 临床前研究,在体外和离体评估阿塔鲁伦对SDS来源细胞的功能恢复作用。
主要发现
- 阿塔鲁伦改善SDS来源细胞的80S核糖体组装和总蛋白合成。
- 阿塔鲁伦恢复髓系祖细胞的髓系生成。
- 阿塔鲁伦改善体外中性粒细胞趋化并减少离体中性粒细胞发育异常标志。
- 阿塔鲁伦在原代成骨细胞中恢复全长SBDS合成,提示其有益作用可能超出髓系区室。
关键数值与推荐
- 约90%的SDS患者存在SBDS基因双等位基因突变,其中约55%携带c.183-184TA>CT无义突变。
- 阿塔鲁伦已在欧洲获批用于治疗Duchenne型肌营养不良症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Shwachman-Diamond syndrome (SDS) is characterized by neutropenia, exocrine pancreatic insufficiency and skeletal abnormalities. SDS bone marrow haematopoietic progenitors show increased apoptosis and impairment in granulocytic differentiation. Loss of Shwachman-Bodian-Diamond syndrome (SBDS) expression results in reduced eukaryotic 80S ribosome maturation. Biallelic mutations in the SBDS gene are found in ~90% of SDS patients, ~55% of whom carry the c.183-184TA>CT nonsense mutation. Several translational readthrough-inducing drugs aimed at suppressing nonsense mutations have been developed. One of these, ataluren, has received approval in Europe for the treatment of Duchenne muscular dystrophy. We previously showed that ataluren can restore full-length SBDS protein synthesis in SDS-derived bone marrow cells. Here, we extend our preclinical study to assess the functional restoration of SBDS capabilities in vitro and ex vivo. Ataluren improved 80S ribosome assembly and total protein synthesis in SDS-derived cells, restored myelopoiesis in myeloid progenitors, improved neutrophil chemotaxis in vitro and reduced neutrophil dysplastic markers ex vivo. Ataluren also restored full-length SBDS synthesis in primary osteoblasts, suggesting that its beneficial role may go beyond the myeloid compartment. Altogether, our results strengthened the rationale for a Phase I/II clinical trial of ataluren in SDS patients who harbour the nonsense mutation.
引用
- Cipolli M, Boni C, Penzo M, et al. Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells. Br J Haematol. 2023. PMID: 37876306. doi:10.1111/bjh.19134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。